Results 31 to 40 of about 1,761 (189)

Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Vaccines, 2022
Hematopoietic stem cell transplant (HSCT) recipients have a high risk of developing primary varicella-zoster virus (VZV) infection and reactivation. VZV vaccination may prevent infection and reactivation.
Michael Koldehoff, Peter A. Horn, Monika Lindemann   +2 more
doaj   +1 more source

Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients

Vaccines, 2022
Solid organ transplant recipients have an up to ninefold higher risk of varicella–zoster virus (VZV) reactivation than the general population. Due to lifelong immunosuppressive therapy, vaccination against VZV may be less effective in kidney transplant ...
Monika Lindemann, Charleen Baumann, Benjamin Wilde, Anja Gäckler, Lara Meller, Peter A. Horn, Adalbert Krawczyk, Oliver Witzke   +7 more
doaj   +1 more source

Increasing second dose Shingrix vaccine compliance in a veteran population using multiple strategies

, 2023
Purpose of Project: The purpose of the project was to measure the compliance rate with the second dose of Shingrix vaccination in a veteran population aged 50 and older using multiple strategic reminders, such as letters, phone calls, handouts, and ...

core   +1 more source

Lichen planus following recombinant zoster vaccine [PDF]

JAAD Case Reports
Charli C. Gruen, 2d Lt, USAF, BS, Bianca N. Coffel, Capt, USAF, MD, Paul Hahn, Lt Col, USA, MD   +2 more
doaj   +2 more sources

Uveitis reactivation following recombinant zoster vaccination

American Journal of Ophthalmology Case Reports, 2021
Purpose: Describe three cases of uveitis reactivation following immunization with recombinant zoster vaccine (RZV). Observations: One patient developed reactivation of previously controlled multifocal choroiditis within one week of receiving RZV ...
Paige J. Richards, Maxwell J. Wingelaar, Karen R. Armbrust, Laura J. Kopplin   +3 more
doaj   +1 more source

Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine

Pharmaceutics, 2022
Varicella zoster virus (VZV) causes two diseases: varicella upon primary infection and herpes zoster when latent viruses in the sensory ganglia reactivate.
Ning Luan, Han Cao, Yunfei Wang, Kangyang Lin, Cunbao Liu   +4 more
doaj   +1 more source

Increased Production of Inflammatory Cytokines after Inoculation with Recombinant Zoster Vaccine in Mice

Vaccines, 2022
Increasing numbers of patients with zoster were reported recently, and recombinant zoster vaccine (Shingrix®) was licensed using the AS01B adjuvant system.
Tetsuo Nakayama, Akihito Sawada, Takeshi Ito   +2 more
doaj   +1 more source

Disparities in uptake of Shingrix® vaccine in immunosuppressed individuals in England: a population-based cohort study [PDF]

Background: Herpes zoster (shingles) impacts health and quality of life, particularly in immunosuppressed individuals. The UK Shingrix® zoster vaccination programme has been available for eligible immunosuppressed individuals since 2021.
Barry EV, Suffel AM, Walker J, Andrews N, Campbell C, Goudie R, de Lusignan S, Leston M, Langan SM, Stowe J, Douglas IJ, Parker EP, Mansfield KE.   +12 more
europepmc   +3 more sources

First case of lupus induced by the Shingrix vaccine: a case report and literature review [PDF]

Clinical Rheumatology
Coral Arevalo-Canas
exaly   +2 more sources

13. Uncommon rash and neurological symptoms related to Shingrix [PDF]

Open Forum Infectious Diseases, 2020
Abstract Background Shingrix is a non-live recombinant vaccine approved by the Food and Drug Administration (FDA) in 2017 to prevent shingles and postherpetic neuralgia in immunocompetent adults age 50 years and older.
Yadava, sanjay K, Mahapatra, Rahul
openaire   +1 more source